Please assess the completion status of the following clinical trial:

Trial Title: Study of MK-1248 With and Without Pembrolizumab (MK-3475) for Participants With Advanced Solid Tumors (MK-1248-001)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically- or cytologically-confirmed metastatic solid tumor for which there is no available therapy that may convey clinical benefit~* Measurable disease by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria~* Performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale~* Adequate organ function~* Female participants of childbearing potential should be willing to use adequate contraception for the course of the study through 120 days after the last dose of study medication~* Male participants should agree to use adequate contraception starting with the first dose of study therapy through 180 days after the last dose of study medication~* Can submit a baseline tumor sample~Exclusion Criteria:~* Has had chemotherapy, radiation, or biological cancer therapy within 4 weeks prior to the first dose of study medication, or not recovered from adverse events due to cancer therapeutics administered more than 4 weeks earlier~* Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of study medication~* Previous treatment with another agent targeting the glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR) receptor~* Previous treatment with an immunomodulatory therapy and was discontinued from that therapy due to an immune-related adverse event~* Expected to require any other form of antineoplastic therapy while on study~* On chronic systemic steroid therapy in excess of replacement doses, or on any other form of immunosuppressive medication~* History of a previous, additional malignancy, unless potentially curative treatment has been completed, with no evidence of malignancy for 5 years with the exception of successful definitive resection of basal cell carcinoma of the skin, superficial bladder cancer or in situ cervical cancer~* Known active central nervous system (CNS) metastases and/or carcinomatous meningitis~* Severe hypersensitivity reaction to treatment with another monoclonal antibody~* Active autoimmune disease or a documented history of autoimmune disease with the exception of vitiligo or resolved childhood asthma/atopy, or endocrine deficiency following treatment with an immunomodulatory agent~* Active infection requiring therapy~* Active or a history of non-infectious pneumonitis~* Prior stem cell or bone marrow transplant~* Known history of human immunodeficiency virus (HIV), active chronic or acute hepatitis B or C~* Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study~* Regular user (including recreational use) of any illicit drugs or had a recent history (within the last year) of substance abuse (including alcohol), at the time of signing informed consent~* Symptomatic ascites or pleural effusion~* Pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the study through 180 days after the last dose of study medication~* Major surgery within 16 weeks prior to screening~* Live vaccine within 30 days prior to first dose of study medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MK-1248 (Type: EXPERIMENTAL): Participants received escalating doses of MK-1248 at assigned dose (dose range: 0.12 mg to 170 mg MK-1248) via intravenous (IV) infusion on Day 1 of each 21-day cycle for up to 4 cycles (up to \~3 months).
- MK-1248 + Pembrolizumab (Type: EXPERIMENTAL): Participants received escalating doses of MK-1248 at assigned dose (dose range: 0.12 mg to 60 mg MK-1248) via IV infusion on Day 1 of each 21-day cycle for a maximum of 4 cycles (up to \~3 months) PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to \~24 months).

Based on this trial design, predict the completion outcome and termination type (if applicable).